Helen Louise Collins is CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN). They have made 1 open-market trade across 1 company since 2024, most recently 2026-09-17.
CIK 0001701247
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FPRX | 135,547 | $5.2M |
| ELVN | 25,000 | $934K |
| Total | $6.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-21 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELVN | SELL · 10b5-1 | 2026-09-17 | 2026-09-21 | $50.35 | $252K | -4.3% | — | — |
| ELVN | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $58.59 | $293K | -1.4% | -15.9% | — |
| ELVN | SELL · 10b5-1 | 2026-07-17 | 2026-07-21 | $52.67 | $263K | +3.0% | +11.0% | — |
| ELVN | SELL · 10b5-1 | 2026-06-17 | 2026-06-22 | $43.80 | $219K | +10.3% | +17.2% | +8.3% |
| ELVN | SELL · 10b5-1 | 2026-05-18 | 2026-05-20 | $39.79 | $199K | -14.4% | +10.8% | +44.6% |
| ELVN | SELL · 10b5-1 | 2026-04-17 | 2026-04-21 | $47.67 | $238K | -10.4% | -9.1% | +11.3% |
| ELVN | SELL · 10b5-1 | 2026-03-25 | 2026-03-27 | $35.10 | $2.8M | +19.1% | +17.3% | +28.2% |
| ELVN | SELL · 10b5-1 | 2026-03-17 | 2026-03-19 | $27.76 | $139K | +29.7% | +53.6% | +48.5% |
| ELVN | SELL | 2026-03-09 | 2026-03-11 | $30.07 | $1.2M | +1.8% | +49.8% | +19.4% |
| ELVN | SELL · 10b5-1 | 2026-02-17 | 2026-02-19 | $26.17 | $1.2M | +10.8% | +18.8% | +61.5% |
| ELVN | SELL · 10b5-1 | 2024-10-18 | 2024-10-22 | $30.00 | $24K | -3.8% | -11.6% | -23.4% |
| ELVN | SELL · 10b5-1 | 2024-04-11 | 2024-04-15 | $25.07 | $501K | -14.3% | +22.6% | +28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.